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Vol.97 (2003) 446LETTERTOTHEEDITORsonide+formoterolwas short-lived, being observed only
after 1 and 2 months of the 3-month study (3). Both
groups were comparable after 3 months. Although in
the present report exacerbation data were strati¢ed by
baseline nighttime awakenings in addition to strati¢ca-
tion by country, analysis of change from baseline would
have beenmore appropriate, leading to a bias-free inter-
pretation of the data.
The unjusti¢able choice of doses (£uticasone dose on
the steep part and budesonide on the top of the dose^
response curve), £awed design and inappropriate statis-
tical analyses undermine thevalidity of this study. Indeed,
to be scienti¢cally reliable, comparative clinical asthma
studies using di¡erent drugs in di¡erent inhalers should
be performed on the steep part of the dose^response
curve and should include at least two doses of one of
the drugs. If not, the results are usually inconclusive (4).
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Dear Sir,
We write in response to publication of the results of
the EDICTstudy, which compares salmeterol/£uticasone
(50/250mg) with budesonide (800mg)+formoterol
(12mg) twice daily (1).This study has a number of serious
£aws that cast doubt on the reliability of its ¢ndings.
The doses at which salmeterol/£uticasone and bude-
sonide+formoterol were compared are inappropriate.
In particular, the dose of budesonide (1600mg/day) was
excessively high and at the top of the dose^response
curve. Busse and colleagues have shown that there is lit-
tle di¡erence in the e⁄cacy of budesonide at 800 and
1600mg/day (2). In addition, as the majority of overall
costs were due to study drug-acquisition costs, this bias
is likely to have resulted in the higher cost of treatment
with budesonide+formoterol.
In the budesonide + formoterol group, patients had to
use three inhalers twice daily. Patients favour using
bronchodilators because of the rapid relief they provide.
Although placebo and study drug inhalers were designed
to look identical, the di¡erence between the fast-acting
formoterol andbudesonide or placebowill havebeen ob-
vious to patients, potentially reducing adherence to bu-
desonide. This again biases the study against
budesonide+formoterol and implies that the results are
unlikely to apply to budesonide/formoterol in a single in-
haler (Symbicorts).
Analyses of exacerbations were performed on total
numbers (mild, moderate and severe events) and mean
rates of exacerbations. As shown in Fig. 3 of the paper,
there was no signi¢cant di¡erence between the two
treatment groups in any of these individual categories.
Combining these categories is clinically meaningless, as
these events have di¡erent health and cost implications.
Di¡erences in the exacerbation rate were almost en-
tirely caused by mild exacerbations, which include
nighttime awakenings. Patients in the budesonide+for-
moterolgrouphad a signi¢cantlyhigher rate of nighttime
awakenings at baselineFa 42% di¡erence in favour of
salmeterol/£uticasone.Despite this di¡erence, data from
this studypresentedbyChuchalin and colleagues showed
that the advantage of salmeterol/£uticasone over bude-
